The cell therapy market continues to mature, with more products successfully reaching late-phase trials and commercial-ready states, yet significant challenges remain. The inherent complexity of cell therapy manufacturing only exacerbates obstacles, from autologous vs. allogeneic modalities to multiple cell types and the unique biological blueprints of patient and donor sourced cells. In a field that presents a myriad of challenges at every phase, cell therapy supply chain efficiency is a critical component in securing timely end-to-end production.
Our expert panel will discuss the crucial parameters for a cell therapy supply chain, from chain of identity to chain of custody and scalability.
This webinar will be targeted to senior technical staff and business development professionals in the pharmaceutical and biotech industries.
Dr. Jef Pinxteren oversees the process and analytical development for Catalent’s Cell Therapy business in Europe. Prior to Catalent, he has headed R&D, Process Development and Operational functions across innovative companies such as Promethera Biosciences and Athersys/ReGenesys. His industry experience is complemented with a solid academic background in progressing research across many cell types. With over 30 years of experience, Jef holds a Ph.D. in Biochemistry from the University of Antwerp and has worked with an EMBO fellowship at University College London. He has also spent time at University of Alabama Birmingham and University of North Carolina in the US. During his professional tenure, he has been managing academic-industrial partnerships across US, Europe and Australia.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.